<DOC>
	<DOCNO>NCT01356940</DOCNO>
	<brief_summary>A randomized placebo control double-blind cross-over trial Dalfampridine ER effect ambulatory activity people multiple sclerosis</brief_summary>
	<brief_title>A Placebo Controlled Trial Dalfampridine ER Ambulatory Activity People With Multiple Sclerosis</brief_title>
	<detailed_description>This parallel-group , double-blind , randomize control crossover trial 1:1 randomization . There two treatment period 4 week two-week treatment washout period . Treatment period DER ( dalfampridine ER ) follow placebo ( group A ) placebo follow DER ( group B ) , respectively . All dosage administer twice week . Purpose study see use study drug ( dalfampridine Er ) short period time improve way subject multiple sclerosis ( MS ) walk .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Diagnosis MS make least 3 month prior base McDonald Proser criterion . Age 1875 year old inclusive . Expanded Disability Status Scale ( EDS ) 06.5 Clinical stability define MS exacerbation change disease modify therapy 60 day prior screen . Screening 6minute walk test distance 50m500m , inclusive . Written informed consent . use 4aminopyridine within 6 month screen Any contraindication DER : Allergy DER history seizure disorder history EEG show epileptiform activity Renal insufficiency ( estimate GFR &lt; 60 . Any condition would exclude 6 minute walk testing : Cardiac surgery myocardial infarction within last 3 month . Severe aortic stenosis hypertropic cardiomyopathy . Pulmonary embolus infarction last 6 month . Uncontrolled hypertension history screen baseline diastolic blood pressure &gt; 170 , systolic blood pressure &gt; 105 . Use oxygen home 24 hours/day severe lung disease . History ventricular arrhythmia find significant ventricular arrhythmia . atrial arrhythmia 2nd 3rd degree heart block screen ECG . Concomitant neurological disease , ALS , Parkinson Disease , stroke . Hospitalization last 6 month psychiatric illness . Alcohol drug abuse within past year . Females breastfeeding , pregnant potential become pregnant course study ( fertile unwilling/unable use effective contraceptive measure ) Cognitive deficit would interfere subject 's ability give inform consent preform study test . Any serious and/or unstable medical condition . Use mitoxantrone ( Novantrone ) within 6 month baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Ambulation</keyword>
</DOC>